Send to

Choose Destination
SICOT J. 2018;4:46. doi: 10.1051/sicotj/2018044. Epub 2018 Nov 5.

Unusual indication of Cell therapy for hip osteonecrosis after pregnancy.

Author information

Hôpital Henri Mondor, 51 avenue du Maréchal de Tassigny, 94000 Creteil, France.
Auregan Jean Charles, Hopital Antoine Beclere, 157 Rue de la Porte de Trivaux, 92140 Clamart, France.



Osteonecrosis is a rare event during or after pregnancy. Due to the low number of cases, there is no report of long-term results after conservative surgery in this population.


From 1992 to 2010, 145 consecutive female patients with unilateral symptomatic (94 stage I and 51 stage II) left hip osteonecrosis (ON) related to pregnancy were treated between 4 and 16 months after delivery with percutaneous mesenchymal stem cell (MSC) injection obtained from bone marrow concentration. The average total number of MSCs (counted as number of colonies forming units-fibroblast) injected in the hip was 185 000 ± 65 000 cells (range 95 000-240 000 cells).


At the most recent follow-up (average 15 years after hip surgery, range 8-25 years), among the 145 hips included in the study, 4 hips (2.7%) had collapsed and were treated with total hip arthroplasty (THA). Thirty-two of the 94 stage I had progressed to stage II; and 4 of the 51 stage II had progressed to stage III and collapse. The other 141 hips (97.3%) were without collapse and pain free. On MRI, as percentage of the volume of the femoral head, the osteonecrosis had decreased from 34.5% pre-operatively to 6% at the most recent follow-up. For women who had other children after treatment, a subsequent pregnancy was not associated with osteonecrosis.


Patients with hip osteonecrosis following pregnancy had a low conversion rate to THA when treated early with cell therapy.

Free full text

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center